Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 3, 2022
- Accepted in final form September 26, 2022
- First Published November 21, 2022.
Author Disclosures
- Anna G. Francis, BMBCh*,
- Kariem Elhadd, MBBS,
- Valentina Camera, MD,
- Monica Ferreira dos Santos, MD,
- Chiara Rocchi, MD,
- Poneh Adib-Samii, MBBS, PhD,
- Bal Athwal, FRCP,
- Kathrine Attfield, PhD,
- Andrew Barritt, MBBS, PhD,
- Matthew Craner, PhD,
- Leonora Fisniku, MD,
- Astrid K.N. Iversen, MD, PhD*,
- Oliver Leach, MBChB,
- Lucy Matthews, MRCP, DPhil,
- Ian Redmond, FRCP,
- Jonathan O'Riordan, MD,
- Antonio Scalfari, MD, PhD,
- Radu Tanasescu, MD, PhD,
- Damian Wren, DM,
- Saif Huda, DPhil,
- Maria Isabel Leite, MD, DPhil*,
- Lars Fugger, MD, PhD* and
- Jacqueline Palace, MD, PhD*
- Anna G. Francis, BMBCh*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kariem Elhadd, MBBS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Valentina Camera, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Monica Ferreira dos Santos, MD,
None
NONE
Speaking honoraria from Merck, commercial, money payment.Support for scientific meetings from Biogen, Merck, Roche, Sanofi-Genzyme, commercial, travel expenses coverage.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Chiara Rocchi, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Poneh Adib-Samii, MBBS, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Bal Athwal, FRCP,
1. Abbvie scientific advisory board2. Teva scientific advisory board
Compensation for consulting1. Abbvie2. Teva
Abbvie - speaker honoraria, commerical entity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrine Attfield, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Barritt, MBBS, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew Craner, PhD,
None
NONE
Commercial for travel and speaker Honoraria from Merck, Novartis, Actelion, Roche, Sanoffi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Leonora Fisniku, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Astrid K.N. Iversen, MD, PhD*,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Oak Foundation (it has nothing to do with this study)
NONE
NONE
NONE
NONE
NONE
NONE
- Oliver Leach, MBChB,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lucy Matthews, MRCP, DPhil,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ian Redmond, FRCP,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan O'Riordan, MD,
None
NONE
Travel and speaker honoraria from Northern Connections
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently principal investigator in commercial studies sponsored by Biogen, Novartis and Teva
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Scalfari, MD, PhD,
None
NONE
Speaker honoraria and funding for travel: Roche, Sanofi, Biogen, Novartis, Celgene.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Radu Tanasescu, MD, PhD,
None
NONE
RT has received support for the attendance of clinical and research conferences from Novartis, Biogen - all outside the submitted work.
Guest editor - Frontiers in Neurology 2021/2022.Guest editor - European Journal of Neurology 2021/2022.
NONE
NONE
NONE
personal compensation for consultancy from Johnson & Johnson Romania, outside the submitted work.
NONE
NONE
NONE
NONE
NONE
NONE
br>RT has received support from UK MRC (CARP MR/T024402/1).
NONE
NONE
NONE
NONE
NONE
NONE
- Damian Wren, DM,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NHS Consultant Neurologist
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Saif Huda, DPhil,
None
NONE
None
NONE
NONE
NONE
NONE
(1) AlphaSights (2) Atheneum
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Isabel Leite, MD, DPhil*,
None
NONE
Dr. Maria Isabel Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis Optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis.
Neuromuscular Disorders, editorial board member, from January 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Fugger, MD, PhD* and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Palace, MD, PhD*
1) Merck Serono 2) Roche 3) ARGENX 4) Novartis 5) UCB 6) Alexion 7)Janssen8) Sanofi
NONE
All commercial (speakers/meetings honorarium last two years)1) Roche 2) Alexion 3) Chugai
Lancet Neurology editorial committee member
ISIS Innovation Ltd. To protect for the use ofmetabolomics as a method to diagnose and stage disease inmultiple sclerosis. Patent ref P37347WO and licence agreement Numares multimarker MS diagnostics
NONE
NONE
Amplo
Please see 3 (speaker/meetings)
NONE
NONE
All commercial (support for research)1) Amplo 2) UCB3) Alexion4)Medimmune
NONE
NONE
Grant for research:1) Multiple Sclerosis Society4) SPARKS Great Ormond Street
Astra Zenica shares
NONE
Patent ref P37347WO and licence agreement Numares multimarker MS diagnostics
NONE
NONE
NONE
- From the Nuffield Department of Clinical Neurology (A.G.F., V.C., M.F.S., K.A., M.C., A.K.N.I., M.I.L., Lars Fugger, J.P.), Oxford University; The Walton Centre NHS Foundation Trust (K.E., C.R.)Neurology Unit (V.C.), Azienda Ospedaliero-Universitaria of Modena, Italy; Neurology (M.F.S.), Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Neurological Clinic (C.R.), Marche Polytechnic University, Ancona, Italy; Department of Neurology (P.A.-S., B.A.), Royal Free London NHS Trust; Department of Neurology (A.B., L.E.), Brighton and Sussex University Hospitals NHS Foundation Trust; Royal Cornwall Hospitals NHS Trust (O.L.); Milton Keynes University Hospital (L.M.); East Kent Hospitals University Foundation Trust (I.R.); Department of Clinical Neurology (J.O.), University of Dundee; Imperial College London (A.S.); Centre of Neuroscience (A.S.), Department of Medicine, Charing Cross Hospital; Division of Clinical Neuroscience (R.T.), University of Nottingham, United Kingdom; Nottingham Centre for Multiple Sclerosis and Neuroinflammation (R.T.), Queen's Medical Centre, Nottingham University Hospitals NHS Trust; Frimley Health NHS Foundation Trust (D.W.); and University of Liverpool (S.H.).
- Correspondence
Dr. Francis anna.francis11{at}yahoo.co.uk
Article usage
Cited By...
Letters: Rapid online correspondence
- Author Response: Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination
- Anna Francis, NMO Clinical Fellow, John Radcliffe Hospital, Oxford
Submitted December 20, 2022 - Reader Response: Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination
- Elias S Sotirchos, Assistant Professor of Neurology, Johns Hopkins University School of Medicine
Submitted December 12, 2022
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.